The case for surgery in obstructive hypertrophic cardiomyopathy

Barry J. Maron, Joseph A. Dearani, Steve R. Ommen, Martin S. Maron, Hartzell V Schaff, Bernard J. Gersh, Rick A. Nishimura

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Relief of left ventricular (LV) outflow obstruction in patients with hypertrophic cardiomyopathy (HCM) and disabling symptoms refractory to maximum medical management has historically been a surgical problem. Surgical septal myectomy permanently abolishes systolic anterior motion of the mitral valve and mitral regurgitation, while normalizing LV pressures and wall stress. Also, these salutary goals are achieved without encumbering patients with post-procedural devices (e.g., pacemakers or defibrillators) or creating potentially arrhythmogenic substrates, as may occur with alcohol septal ablation. Procedural morbidity and mortality risk with myectomy is similar to, and in some institutions less than those for alcohol septal ablation. Over four decades, reports from numerous centers worldwide have consistently and unequivocably documented the benefits of surgery on hemodynamic and functional state, restoring normal and acceptable quality of life to patients of all ages by largely reversing the complications of heart failure. Long-term survival after myectomy is similar to that of the general population and superior to non-operated patients with obstruction. The LV outflow tract morphology in HCM is heterogeneous and not uncommonly includes congenital anomalies of the mitral valve apparatus for which the surgeon has the flexibility to adapt the repair, often employing an extended myectomy. In the current atmosphere of increasing and perhaps excessive enthusiasm for newer catheter-based interventions, it is a critical time to promote and re-emphasize that surgery is the time-honored (and presently the most effective) treatment strategy for relieving heart failure-related disability resulting from dynamic LV outflow obstruction in HCM, and is the primary treatment option for this subgroup of severely symptomatic drug-refractory patients.

Original languageEnglish (US)
Pages (from-to)2044-2053
Number of pages10
JournalJournal of the American College of Cardiology
Volume44
Issue number10
DOIs
StatePublished - Nov 16 2004

Fingerprint

Hypertrophic Cardiomyopathy
Ventricular Outflow Obstruction
Mitral Valve Insufficiency
Heart Failure
Alcohols
Defibrillators
Ventricular Pressure
Atmosphere
Mitral Valve
Catheters
Hemodynamics
Quality of Life
Morbidity
Equipment and Supplies
Survival
Mortality
Therapeutics
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Maron, B. J., Dearani, J. A., Ommen, S. R., Maron, M. S., Schaff, H. V., Gersh, B. J., & Nishimura, R. A. (2004). The case for surgery in obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 44(10), 2044-2053. https://doi.org/10.1016/j.jacc.2004.04.063

The case for surgery in obstructive hypertrophic cardiomyopathy. / Maron, Barry J.; Dearani, Joseph A.; Ommen, Steve R.; Maron, Martin S.; Schaff, Hartzell V; Gersh, Bernard J.; Nishimura, Rick A.

In: Journal of the American College of Cardiology, Vol. 44, No. 10, 16.11.2004, p. 2044-2053.

Research output: Contribution to journalArticle

Maron, BJ, Dearani, JA, Ommen, SR, Maron, MS, Schaff, HV, Gersh, BJ & Nishimura, RA 2004, 'The case for surgery in obstructive hypertrophic cardiomyopathy', Journal of the American College of Cardiology, vol. 44, no. 10, pp. 2044-2053. https://doi.org/10.1016/j.jacc.2004.04.063
Maron, Barry J. ; Dearani, Joseph A. ; Ommen, Steve R. ; Maron, Martin S. ; Schaff, Hartzell V ; Gersh, Bernard J. ; Nishimura, Rick A. / The case for surgery in obstructive hypertrophic cardiomyopathy. In: Journal of the American College of Cardiology. 2004 ; Vol. 44, No. 10. pp. 2044-2053.
@article{0851bb1589ec4a3197a9a09295fa3d92,
title = "The case for surgery in obstructive hypertrophic cardiomyopathy",
abstract = "Relief of left ventricular (LV) outflow obstruction in patients with hypertrophic cardiomyopathy (HCM) and disabling symptoms refractory to maximum medical management has historically been a surgical problem. Surgical septal myectomy permanently abolishes systolic anterior motion of the mitral valve and mitral regurgitation, while normalizing LV pressures and wall stress. Also, these salutary goals are achieved without encumbering patients with post-procedural devices (e.g., pacemakers or defibrillators) or creating potentially arrhythmogenic substrates, as may occur with alcohol septal ablation. Procedural morbidity and mortality risk with myectomy is similar to, and in some institutions less than those for alcohol septal ablation. Over four decades, reports from numerous centers worldwide have consistently and unequivocably documented the benefits of surgery on hemodynamic and functional state, restoring normal and acceptable quality of life to patients of all ages by largely reversing the complications of heart failure. Long-term survival after myectomy is similar to that of the general population and superior to non-operated patients with obstruction. The LV outflow tract morphology in HCM is heterogeneous and not uncommonly includes congenital anomalies of the mitral valve apparatus for which the surgeon has the flexibility to adapt the repair, often employing an extended myectomy. In the current atmosphere of increasing and perhaps excessive enthusiasm for newer catheter-based interventions, it is a critical time to promote and re-emphasize that surgery is the time-honored (and presently the most effective) treatment strategy for relieving heart failure-related disability resulting from dynamic LV outflow obstruction in HCM, and is the primary treatment option for this subgroup of severely symptomatic drug-refractory patients.",
author = "Maron, {Barry J.} and Dearani, {Joseph A.} and Ommen, {Steve R.} and Maron, {Martin S.} and Schaff, {Hartzell V} and Gersh, {Bernard J.} and Nishimura, {Rick A.}",
year = "2004",
month = "11",
day = "16",
doi = "10.1016/j.jacc.2004.04.063",
language = "English (US)",
volume = "44",
pages = "2044--2053",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - The case for surgery in obstructive hypertrophic cardiomyopathy

AU - Maron, Barry J.

AU - Dearani, Joseph A.

AU - Ommen, Steve R.

AU - Maron, Martin S.

AU - Schaff, Hartzell V

AU - Gersh, Bernard J.

AU - Nishimura, Rick A.

PY - 2004/11/16

Y1 - 2004/11/16

N2 - Relief of left ventricular (LV) outflow obstruction in patients with hypertrophic cardiomyopathy (HCM) and disabling symptoms refractory to maximum medical management has historically been a surgical problem. Surgical septal myectomy permanently abolishes systolic anterior motion of the mitral valve and mitral regurgitation, while normalizing LV pressures and wall stress. Also, these salutary goals are achieved without encumbering patients with post-procedural devices (e.g., pacemakers or defibrillators) or creating potentially arrhythmogenic substrates, as may occur with alcohol septal ablation. Procedural morbidity and mortality risk with myectomy is similar to, and in some institutions less than those for alcohol septal ablation. Over four decades, reports from numerous centers worldwide have consistently and unequivocably documented the benefits of surgery on hemodynamic and functional state, restoring normal and acceptable quality of life to patients of all ages by largely reversing the complications of heart failure. Long-term survival after myectomy is similar to that of the general population and superior to non-operated patients with obstruction. The LV outflow tract morphology in HCM is heterogeneous and not uncommonly includes congenital anomalies of the mitral valve apparatus for which the surgeon has the flexibility to adapt the repair, often employing an extended myectomy. In the current atmosphere of increasing and perhaps excessive enthusiasm for newer catheter-based interventions, it is a critical time to promote and re-emphasize that surgery is the time-honored (and presently the most effective) treatment strategy for relieving heart failure-related disability resulting from dynamic LV outflow obstruction in HCM, and is the primary treatment option for this subgroup of severely symptomatic drug-refractory patients.

AB - Relief of left ventricular (LV) outflow obstruction in patients with hypertrophic cardiomyopathy (HCM) and disabling symptoms refractory to maximum medical management has historically been a surgical problem. Surgical septal myectomy permanently abolishes systolic anterior motion of the mitral valve and mitral regurgitation, while normalizing LV pressures and wall stress. Also, these salutary goals are achieved without encumbering patients with post-procedural devices (e.g., pacemakers or defibrillators) or creating potentially arrhythmogenic substrates, as may occur with alcohol septal ablation. Procedural morbidity and mortality risk with myectomy is similar to, and in some institutions less than those for alcohol septal ablation. Over four decades, reports from numerous centers worldwide have consistently and unequivocably documented the benefits of surgery on hemodynamic and functional state, restoring normal and acceptable quality of life to patients of all ages by largely reversing the complications of heart failure. Long-term survival after myectomy is similar to that of the general population and superior to non-operated patients with obstruction. The LV outflow tract morphology in HCM is heterogeneous and not uncommonly includes congenital anomalies of the mitral valve apparatus for which the surgeon has the flexibility to adapt the repair, often employing an extended myectomy. In the current atmosphere of increasing and perhaps excessive enthusiasm for newer catheter-based interventions, it is a critical time to promote and re-emphasize that surgery is the time-honored (and presently the most effective) treatment strategy for relieving heart failure-related disability resulting from dynamic LV outflow obstruction in HCM, and is the primary treatment option for this subgroup of severely symptomatic drug-refractory patients.

UR - http://www.scopus.com/inward/record.url?scp=8344290546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8344290546&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2004.04.063

DO - 10.1016/j.jacc.2004.04.063

M3 - Article

VL - 44

SP - 2044

EP - 2053

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 10

ER -